Almanack Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Almanack Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405K	Buy	+649	New	+$442K	0.05%	189
2024 Q3	–	Sell	-2,411	Closed	-$2.53M	–	189
2024 Q2	$2.53M	Sell	2,411 -2,996	-55%	-$2.9M	0.43%	42
2024 Q1	$5.2M	Buy	5,407 +2,807	+108%	+$2.67M	0.89%	27
2023 Q4	$2.28M	Sell	2,600 -3,800	-59%	-$3.13M	0.42%	38
2023 Q3	$5.27M	Sell	6,400 -800	-11%	-$629K	1.02%	18
2023 Q2	$5.17M	Buy	7,200 +2,200	+44%	+$1.7M	0.91%	19
2023 Q1	$4.11M	Sell	5,000 -6,300	-56%	-$4.75M	0.81%	21
2022 Q4	$8.15M	Buy	+11,300	New	+$8.34M	1.74%	11

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Almanack Investment Partners's REGN Position: Q2 2026 in Review

Almanack Investment Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 649 shares worth $405K. The stake represents 0.05% of the portfolio and ranks #189 among its holdings. This is a return to the name: Almanack Investment Partners previously reported a position in REGN as recently as Q2 2024.

Almanack Investment Partners first reported a position in REGN in Q4 2022 and has held it in 8 quarters since. The position peaked at $8.15M in Q4 2022. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Almanack Investment Partners held 649 shares of Regeneron Pharmaceuticals worth $405K as of Q2 2026.
Regeneron Pharmaceuticals was a new Almanack Investment Partners position in Q2 2026.
Regeneron Pharmaceuticals made up 0.05% of Almanack Investment Partners's portfolio in Q2 2026, its #189 holding.
Almanack Investment Partners first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
Almanack Investment Partners's Regeneron Pharmaceuticals position peaked at $8.15M in Q4 2022.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.